<div class="infobox">
<div class="infobox-header">Ferroptosis in 4R-Tauopathies Overview</div>
<div class="infobox-content">
<table>
<tr><th>Diseases Covered</th><td>PSP, CBD, AGD, GGT, FTDP-17</td></tr>
<tr><th>Key Pathway</th><td>GPX4-dependent lipid peroxidation</td></tr>
<tr><th>Iron Role</th><td>Essential catalyst, potential therapeutic target</td></tr>
<tr><th>Therapeutic Focus</th><td>Lipid peroxidation inhibitors, iron chelation</td></tr>
</table>
</div>
</div>
Ferroptosis is an iron-dependent, non-apoptotic form of cell death characterized by lipid peroxidation accumulation. Originally described in cancer biology, ferroptosis has emerged as a relevant cell death mechanism in neurodegenerative diseases, including the 4R-tauopathies (progressive supranuclear palsy, corticobasal degeneration, argyrophilic grain disease, globular glial tauopathy, and frontotemporal dementia with parkinsonism-17).
The 4R-tauopathies share a common pathology of 4-repeat tau filament accumulation, but exhibit distinct regional vulnerabilities and clinical phenotypes. Ferroptosis provides a mechanistic framework for understanding how iron dysregulation and lipid peroxidation contribute to neuronal loss across these diseases.
<div class="infobox">
<div class="infobox-header">Ferroptosis in 4R-Tauopathies Overview</div>
<div class="infobox-content">
<table>
<tr><th>Diseases Covered</th><td>PSP, CBD, AGD, GGT, FTDP-17</td></tr>
<tr><th>Key Pathway</th><td>GPX4-dependent lipid peroxidation</td></tr>
<tr><th>Iron Role</th><td>Essential catalyst, potential therapeutic target</td></tr>
<tr><th>Therapeutic Focus</th><td>Lipid peroxidation inhibitors, iron chelation</td></tr>
</table>
</div>
</div>
Ferroptosis is an iron-dependent, non-apoptotic form of cell death characterized by lipid peroxidation accumulation. Originally described in cancer biology, ferroptosis has emerged as a relevant cell death mechanism in neurodegenerative diseases, including the 4R-tauopathies (progressive supranuclear palsy, corticobasal degeneration, argyrophilic grain disease, globular glial tauopathy, and frontotemporal dementia with parkinsonism-17).
The 4R-tauopathies share a common pathology of 4-repeat tau filament accumulation, but exhibit distinct regional vulnerabilities and clinical phenotypes. Ferroptosis provides a mechanistic framework for understanding how iron dysregulation and lipid peroxidation contribute to neuronal loss across these diseases.
Glutathione peroxidase 4 (GPX4) is the central regulator of ferroptosis. GPX4 reduces lipid hydroperoxides to corresponding alcohols, preventing membrane damage. When GPX4 is inhibited or depleted, accumulated lipid peroxides trigger ferroptotic cell death.
| Component | Function | Therapeutic Target |
|-----------|----------|-------------------|
| GPX4 | Reduces lipid peroxides | GPX4 activators |
| GSH | GPX4 cofactor | GSH precursors |
| Iron (Fe²⁺) | Catalyzes ROS generation | Iron chelation |
| ACSL4 | Incorporates PUFA into lipids | ACSL4 inhibitors |
| NCOA4 | Mediates ferritinophagy | NCOA4 modulators |
PSP shows prominent iron accumulation in the globus pallidus and subthalamic nucleus, regions that also exhibit severe tau pathology. The iron-tau relationship in PSP includes:
CBD exhibits cortical and basal ganglia involvement with iron dysregulation:
AGD shows relatively milder iron involvement compared to PSP and CBD:
GGT demonstrates unique iron relationships due to glial pathology:
Hereditary tauopathies show iron dysregulation based on specific mutations:
Iron and tau pathology interact through multiple mechanisms:
Polyunsaturated fatty acids (PUFAs) in neuronal membranes are susceptible to iron-catalyzed oxidation. The resulting lipid hydroperoxides accumulate when GPX4 activity is compromised.
GPX4 expression and activity are reduced in tauopathies through:
| Therapeutic Approach | Mechanism | Development Status |
|---------------------|-----------|-------------------|
| Iron chelation | Deferoxamine, Deferasirox | Preclinical |
| GPX4 activators | Selenium, Vitamin E | Preclinical |
| Lipoxygenase inhibitors | Zileuton, PD-146176 | Preclinical |
| Ferroptosis inhibitors | Ferrostatin-1 analogs | Discovery |
| NCOA4 modulators | Autophagy modulation | Discovery |
Iron chelation represents a promising approach for 4R-tauopathies with iron accumulation:
Preventing lipid peroxide accumulation may protect neurons:
| Disease | Primary Regions | Severity | Cell Types Affected |
|---------|-----------------|-----------|---------------------|
| PSP | Globus pallidus, SN | High | Neurons, microglia |
| CBD | Motor cortex, BG | Moderate-high | Neurons, astrocytes |
| AGD | Limbic system | Moderate | Neurons |
| GGT | White matter | Moderate | Oligodendrocytes |
| FTDP-17 | Variable by mutation | Variable | Neurons |
| Marker | PSP | CBD | AGD | GGT | FTDP-17 |
|--------|-----|-----|-----|-----|---------|
| GPX4 ↓ | +++ | ++ | + | ++ | ++ |
| 4-HNE | +++ | ++ | + | ++ | ++ |
| Ferritin ↑ | +++ | ++ | + | ++ | ++ |
| ACSL4 | ++ | ++ | + | + | + |
Legend: +++ high, ++ moderate, + mild
| Biomarker | Source | Represents |
|-----------|--------|------------|
| 4-HNE | CSF, plasma | Lipid peroxidation |
| Ferritin | CSF, plasma | Iron status |
| GPX4 activity | Blood | Ferroptosis susceptibility |
| Iron | CSF | Free iron levels |
Key research priorities for ferroptosis in 4R-tauopathies:
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
The following diagram shows the key molecular relationships involving ferroptosis-4r-tauopathies discovered through SciDEX knowledge graph analysis: